Genome sequences of 36 Streptococcus pneumoniae strains optimized for the multiplexed opsonophagocytosis killing assay.

Autor:	Graffice E; 1Department of Medicine, Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA., Meewes C; 1Department of Medicine, Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA., Ganaie FA; Division of Pulmonary/Allergy/Critical Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Nahm MH; Division of Pulmonary/Allergy/Critical Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Calix JJ; 1Department of Medicine, Division of Infectious Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jazyk:	angličtina
Zdroj:	Microbiology resource announcements [Microbiol Resour Announc] 2024 Sep 10; Vol. 13 (9), pp. e0055324. Date of Electronic Publication: 2024 Aug 20.
DOI:	10.1128/mra.00553-24
Abstrakt:	A multiplexed opsonophagocytosis assay (MOPA) was developed as a cost-effective, high-throughput biological assay to evaluate the efficacy of pneumococcal vaccines by in vitro measurement of opsonophagocytic activity of anti-capsular antibodies. Here, we report draft genomes of the 36 strains of Streptococcus pneumoniae developed for use in the reference pneumococcal MOPA. Competing Interests: The University of Alabama at Birmingham (UAB) has intellectual property rights to several opsonophagocytosis assay reagents developed in M.H.N.'s laboratory. All authors are affiliated with UAB.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu